The Expression Of ERCC1、TUBB3and KRAS In Non-small Cell Lung Cancer Tissue And Their Clinical Significance

ObjectiveTo investigate the relationship between the gene mutation or expression and relevant clinical and pathologic data by means of detecting the mutations to KRAS gene and the expression to ERCC1and TUBB3for non-small cell lung cancer,in order to supply the reference of individualized treatment for NSCLC.Methods1.the expression of ERCC1mRNA and TUBB3mRNA were detected by Real-time fluorescence quantitative PCR in tumor tissues of88cases NSCLC and peripheral bloods of30cases, comparise which as contrast groups in normal tissue away from the cancer of30cases.the relationship was analyzed between the expression of ERCC1mRNA and TUBB3mRNA and the clinical characteristics and prognosis.2.the mutations of KRAS gene was detected by means of Real-time PCR in29tumor tissue.Results1.There was no relation between the expression of ERCC1mRNA and the clinical characteristics including gender, age, histological type, degree of differentiation and TNM stage(p>0.05).The expression of ERCC1mRNA in peripheral bloods was no correlates with the expression in tumor tissues(p>0.05). The expression of ERCClmRNA in tumor tissues were higher than the expression in peripheral bloods and paracancerous tissues (P<0.05)2.There was no relation between the TUBB3expression and the clinical characteristics including gender, age, histological type, degree of differentiation and TNM stage(p>0.05). The expression of TUBB3mRNA in peripheral bloods was no correlates with the expression in tumor tissues(p>0.05). The expression of TUBB3mRNA in tumor tissues were higher than the expression in peripheral bloods and paracancerous tissues (P<0.05)3.For88cases, the patients with lower expression of ERCC1had longer DFS(39months Vs18months, P=0.003)and OS (59months Vs30months, P=0.002) than those with higher expression.4.Patients with lower expression of TUBB3had longer OS (51months Vs32months, P=0.023) than those with higher expression, and DFS was no statistically significant.5.Patients with lower ERCC1and TUBB3expressions had longer DFS (P=0.006) time and OS (P=0.003) time than those with higher expressions.6.COX multivariate analysis showed that higher ERCC1expression、higher TUBB3expression and TNM stage are independent prognostic factors for NSCLC.7.the fewer case had not be analyzized statistically because the KRAS gene mutated in2cases (6.9%) among29cases.Conclusion1.There was no the correlation between the expression of ERCC1mRNA and TUBB3mRNA and gender/age/histological type/degrees of differentiation/TNM stage.2. The expression of ERCC1mRNA and TUBB3mRNA in tumor tissues were higher than the expression in peripheral bloods and paracancerous tissues (P<0.05).3.The expression of ERCC1mRNA and TUBB3mRNA in peripheral bloods was no correlates with the expression in tumor tissues.4.The patients had longer survive time for the lower expression of ERCC1mRNA and TUBB3mRNA than those for the high expression.5.The expression of ERCC1mRNA and TUBB3mRNA in patients with Ⅱ～ⅢA period NSCLC might be effectively predictive factor for adjuvant chemotherapy sensitivity and the prognosis. The combined evaluation of ERCC1and TUBB3 expression can promote the individual treatment in NSCLC.